Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Niacinamide butyrate is a butyrate-based ionic liquid (IL) composed of a niacinamide (nicotinamide) cation and a butyrate anion. It is primarily investigated as a functional pharmaceutical ingredient or solvent to enhance the oral bioavailability and therapeutic efficacy of poorly soluble drugs, such as glycyrol. Beyond its role as a delivery vehicle, it exhibits intrinsic biological activity; butyrate acts as a histone deacetylase (HDAC) inhibitor and a source of energy for colonocytes, while niacinamide is a precursor to nicotinamide adenine dinucleotide (NAD+). In preclinical models of colorectal cancer, niacinamide butyrate has demonstrated synergistic anti-tumor effects when combined with other phytochemicals by modulating apoptotic pathways and improving drug solubility.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on niacinamide butyrate.